Consensus Recommendations for a Dynamic Susceptibility Contrast MRI Protocol for Use in High-Grade Gliomas.

Despite the widespread clinical use of dynamic susceptibility contrast (DSC) MRI, DSC-MRI methodology has not been standardized, hindering its utilization for response assessment in multi-center trials. Recently, the DSC-MRI Standardization Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition issued an updated consensus DSC-MRI protocol compatible with BTIP, the standardized brain tumor imaging protocol for high-grade gliomas that is increasingly used in the clinical setting and is the default MRI protocol for the National Clinical Trials Network. After reviewing the basis for controversy over DSC-MRI protocols, this manuscript provides evidence-based best practices for clinical DSC-MRI as determined by the Committee, including pulse sequence (gradient echo vs. spin echo), BTIP-compliant contrast agent dosing (preload and bolus), flip angle (FA), echo time (TE), and post-processing leakage correction. In summary, full-dose preload, full-dose bolus dosing using intermediate (60°) FA and field strength-dependent TE (40-50ms at 1.5T, 20-35ms at 3T) provides overall best accuracy and precision for cerebral blood volume estimates. When single-dose contrast agent usage is desired, no-preload, full-dose bolus dosing using low FA (30°) and field strength-dependent TE provides excellent performance, with reduced contrast agent usage and elimination of potential systematic errors introduced by variations in preload dose and incubation time.

[1]  J. Boxerman,et al.  Moving Toward a Consensus DSC-MRI Protocol: Validation of a Low–Flip Angle Single-Dose Option as a Reference Standard for Brain Tumors , 2019, American Journal of Neuroradiology.

[2]  Thomas E. Yankeelov,et al.  Evaluating Multisite rCBV Consistency from DSC-MRI Imaging Protocols and Postprocessing Software Across the NCI Quantitative Imaging Network Sites Using a Digital Reference Object (DRO) , 2019, Tomography.

[3]  J. Boxerman,et al.  Optimization of Acquisition and Analysis Methods for Clinical Dynamic Susceptibility Contrast MRI Using a Population-Based Digital Reference Object , 2018, American Journal of Neuroradiology.

[4]  P. Bogner,et al.  Quantitative comparison of delayed ferumoxytol T1 enhancement with immediate gadoteridol enhancement in high grade gliomas , 2018, Magnetic resonance in medicine.

[5]  B Erickson,et al.  Multisite Concordance of DSC-MRI Analysis for Brain Tumors: Results of a National Cancer Institute Quantitative Imaging Network Collaborative Project , 2018, American Journal of Neuroradiology.

[6]  Benjamin M Ellingson,et al.  Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma , 2017, American journal of clinical oncology.

[7]  Natenael B. Semmineh,et al.  A Population-Based Digital Reference Object (DRO) for Optimizing Dynamic Susceptibility Contrast (DSC)-MRI Methods for Clinical Trials , 2017, Tomography.

[8]  J. Boxerman,et al.  Effects of MRI Protocol Parameters, Preload Injection Dose, Fractionation Strategies, and Leakage Correction Algorithms on the Fidelity of Dynamic-Susceptibility Contrast MRI Estimates of Relative Cerebral Blood Volume in Gliomas , 2017, American Journal of Neuroradiology.

[9]  Diana Delgado,et al.  MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis , 2017, Neuro-oncology.

[10]  Wade M Mueller,et al.  Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics , 2017, Journal of Neuro-Oncology.

[11]  Eric S. Paulson,et al.  Spiral Perfusion Imaging With Consecutive Echoes (SPICE™) for the Simultaneous Mapping of DSC- and DCE-MRI Parameters in Brain Tumor Patients: Theory and Initial Feasibility , 2016, Tomography.

[12]  J. Boxerman,et al.  Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)‐MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab , 2016, Journal of magnetic resonance imaging : JMRI.

[13]  Ashley M Stokes,et al.  Assessment of a simplified spin and gradient echo (sSAGE) approach for human brain tumor perfusion imaging. , 2016, Magnetic resonance imaging.

[14]  J L Boxerman,et al.  Improved Leakage Correction for Single-Echo Dynamic Susceptibility Contrast Perfusion MRI Estimates of Relative Cerebral Blood Volume in High-Grade Gliomas by Accounting for Bidirectional Contrast Agent Exchange , 2016, American Journal of Neuroradiology.

[15]  D. Mankoff,et al.  ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI , 2016, Clinical Cancer Research.

[16]  B. Erickson,et al.  Impact of Software Modeling on the Accuracy of Perfusion MRI in Glioma , 2015, American Journal of Neuroradiology.

[17]  Jingping Xie,et al.  Assessing tumor cytoarchitecture using multiecho DSC‐MRI derived measures of the transverse relaxivity at tracer equilibrium (TRATE) , 2015, Magnetic resonance in medicine.

[18]  Marion Smits,et al.  Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. , 2015, Neuro-oncology.

[19]  J. Kalpathy-Cramer,et al.  Repeatability of Standardized and Normalized Relative CBV in Patients with Newly Diagnosed Glioblastoma , 2015, American Journal of Neuroradiology.

[20]  S. Heiland,et al.  Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma. , 2015, Neuro-Oncology.

[21]  A Gregory Sorensen,et al.  Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. , 2015, Neuro-oncology.

[22]  David Bonekamp,et al.  Association of overall survival in patients with newly diagnosed glioblastoma with contrast‐enhanced perfusion MRI: Comparison of intraindividually matched T1‐ and T2*‐based bolus techniques , 2015, Journal of magnetic resonance imaging : JMRI.

[23]  M Wintermark,et al.  ASFNR Recommendations for Clinical Performance of MR Dynamic Susceptibility Contrast Perfusion Imaging of the Brain , 2015, American Journal of Neuroradiology.

[24]  A. Omuro,et al.  Diffusion and Perfusion MRI to Differentiate Treatment-Related Changes Including Pseudoprogression from Recurrent Tumors in High-Grade Gliomas with Histopathologic Evidence , 2015, American Journal of Neuroradiology.

[25]  T. Cloughesy,et al.  MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab , 2015, Journal of Neuro-Oncology.

[26]  E. Melhem,et al.  Association of dynamic susceptibility contrast enhanced MR Perfusion parameters with prognosis in elderly patients with glioblastomas , 2015, European Radiology.

[27]  T. Cloughesy,et al.  Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab , 2014, Cancer Imaging.

[28]  W. Mueller,et al.  Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. , 2014, Neuro-oncology.

[29]  Namkug Kim,et al.  Which combination of MR imaging modalities is best for predicting recurrent glioblastoma? Study of diagnostic accuracy and reproducibility. , 2014, Radiology.

[30]  D. Aquino,et al.  Parametric Response Maps of Perfusion MRI May Identify Recurrent Glioblastomas Responsive to Bevacizumab and Irinotecan , 2014, PloS one.

[31]  P. Marsden,et al.  Angiogenesis in glioblastoma. , 2013, The New England journal of medicine.

[32]  Fernando Calamante,et al.  The 39 steps: evading error and deciphering the secrets for accurate dynamic susceptibility contrast MRI , 2013, NMR in biomedicine.

[33]  Timothy A. Chan,et al.  MRI perfusion in determining pseudoprogression in patients with glioblastoma. , 2013, Clinical imaging.

[34]  G. Zaharchuk,et al.  Combined spin‐ and gradient‐echo perfusion‐weighted imaging , 2012, Magnetic resonance in medicine.

[35]  Benjamin M Ellingson,et al.  Comparison between intensity normalization techniques for dynamic susceptibility contrast (DSC)‐MRI estimates of cerebral blood volume (CBV) in human gliomas , 2012, Journal of magnetic resonance imaging : JMRI.

[36]  J. Boxerman,et al.  The Role of Preload and Leakage Correction in Gadolinium-Based Cerebral Blood Volume Estimation Determined by Comparison with MION as a Criterion Standard , 2012, American Journal of Neuroradiology.

[37]  Leland S. Hu,et al.  Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival , 2012, Neuro-oncology.

[38]  J. Debbins,et al.  Correlations between Perfusion MR Imaging Cerebral Blood Volume, Microvessel Quantification, and Clinical Outcome Using Stereotactic Analysis in Recurrent High-Grade Glioma , 2012, American Journal of Neuroradiology.

[39]  J. Burdette,et al.  Does MR Perfusion Imaging Impact Management Decisions for Patients with Brain Tumors? A Prospective Study , 2011, American Journal of Neuroradiology.

[40]  Xin Li,et al.  Improved perfusion MR imaging assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model with ferumoxytol. , 2011, Radiology.

[41]  Kim Mouridsen,et al.  T1- and T*2-Dominant Extravasation Correction in DSC-MRI: Part I—Theoretical Considerations and Implications for Assessment of Tumor Hemodynamic Properties , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[42]  D. Hammoud,et al.  Predicting outcome of children with diffuse intrinsic pontine gliomas using multiparametric imaging. , 2011, Neuro-oncology.

[43]  D. Hoffmann,et al.  Prognostic value of perfusion MR imaging in patients with oligodendroglioma: A survival study. , 2011, Journal of neuroradiology. Journal de neuroradiologie.

[44]  D. Kong,et al.  Diagnostic Dilemma of Pseudoprogression in the Treatment of Newly Diagnosed Glioblastomas: The Role of Assessing Relative Cerebral Blood Flow Volume and Oxygen-6-Methylguanine-DNA Methyltransferase Promoter Methylation Status , 2011, American Journal of Neuroradiology.

[45]  K. Schmainda,et al.  Standardization of relative cerebral blood volume (rCBV) image maps for ease of both inter‐ and intrapatient comparisons , 2010, Magnetic resonance in medicine.

[46]  Jianhui Zhong,et al.  Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. , 2010, Radiology.

[47]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Ru-Fang Yeh,et al.  Glioblastoma multiforme regional genetic and cellular expression patterns: influence on anatomic and physiologic MR imaging. , 2010, Radiology.

[49]  J. Debbins,et al.  Optimized Preload Leakage-Correction Methods to Improve the Diagnostic Accuracy of Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging in Posttreatment Gliomas , 2010, American Journal of Neuroradiology.

[50]  M. Berger,et al.  Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. , 2009, Radiology.

[51]  M. J. van den Bent,et al.  Pseudoprogression and pseudoresponse in the treatment of gliomas , 2009, Current opinion in neurology.

[52]  T E Yankeelov,et al.  A theoretical framework to model DSC-MRI data acquired in the presence of contrast agent extravasation , 2009, Physics in medicine and biology.

[53]  Ronald L. Wolf,et al.  Posttreatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction. , 2009, Radiology.

[54]  J E Heiserman,et al.  Relative Cerebral Blood Volume Values to Differentiate High-Grade Glioma Recurrence from Posttreatment Radiation Effect: Direct Correlation between Image-Guided Tissue Histopathology and Localized Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging Measurements , 2009, American Journal of Neuroradiology.

[55]  K. Schmainda,et al.  Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. , 2008, Radiology.

[56]  R M Weisskoff,et al.  Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. , 2006, AJNR. American journal of neuroradiology.

[57]  Glyn Johnson,et al.  Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging--prediction of patient clinical response. , 2006, Radiology.

[58]  B. D. Ward,et al.  Improving the reliability of obtaining tumor hemodynamic parameters in the presence of contrast agent extravasation , 2005, Magnetic resonance in medicine.

[59]  H. Inoue,et al.  Three-dimensional observations on microvascular growth in rat glioma using a vascular casting method , 2005, Journal of Cancer Research and Clinical Oncology.

[60]  B. D. Ward,et al.  Characterization of a first-pass gradient-echo spin-echo method to predict brain tumor grade and angiogenesis. , 2004, AJNR. American journal of neuroradiology.

[61]  F Ståhlberg,et al.  Effects of echo time variation on perfusion assessment using dynamic susceptibility contrast MR imaging at 3 tesla. , 2004, Magnetic resonance imaging.

[62]  Linda Knutsson,et al.  Aspects on the accuracy of cerebral perfusion parameters obtained by dynamic susceptibility contrast MRI: a simulation study. , 2004, Magnetic resonance imaging.

[63]  A. Pathak,et al.  Antiangiogenic effects of dexamethasone in 9L gliosarcoma assessed by MRI cerebral blood volume maps. , 2003, Neuro-oncology.

[64]  R. Frayne,et al.  Signal‐to‐noise ratio effects in quantitative cerebral perfusion using dynamic susceptibility contrast agents , 2003, Magnetic resonance in medicine.

[65]  Glyn Johnson,et al.  Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. , 2002, Radiology.

[66]  M. Takahashi,et al.  Perfusion-sensitive MR imaging of gliomas: comparison between gradient-echo and spin-echo echo-planar imaging techniques. , 2001, AJNR. American journal of neuroradiology.

[67]  M A Viergever,et al.  Simultaneous quantitative cerebral perfusion and Gd‐DTPA extravasation measurement with dual‐echo dynamic susceptibility contrast MRI , 2000, Magnetic resonance in medicine.

[68]  A P Pathak,et al.  Utility of simultaneously acquired gradient‐echo and spin‐echo cerebral blood volume and morphology maps in brain tumor patients , 2000, Magnetic resonance in medicine.

[69]  B. Rosen,et al.  High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[70]  B. Rosen,et al.  Signal‐to‐noise analysis of cerebral blood volume maps from dynamic NMR imaging studies , 1997, Journal of magnetic resonance imaging : JMRI.

[71]  B. Rosen,et al.  High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis , 1996, Magnetic resonance in medicine.

[72]  B R Rosen,et al.  Mr contrast due to intravascular magnetic susceptibility perturbations , 1995, Magnetic resonance in medicine.

[73]  W. J. Lorenz,et al.  Quantification of regional cerebral blood flow and volume with dynamic susceptibility contrast-enhanced MR imaging. , 1994, Radiology.

[74]  B. Rosen,et al.  Microscopic susceptibility variation and transverse relaxation: Theory and experiment , 1994, Magnetic resonance in medicine.

[75]  E F Halpern,et al.  Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. , 1994, Radiology.

[76]  T Kubota,et al.  Tumor vascularity in the brain: evaluation with dynamic susceptibility-contrast MR imaging. , 1993, Radiology.

[77]  B. Rosen,et al.  Functional mapping of the human visual cortex by magnetic resonance imaging. , 1991, Science.

[78]  B. Rosen,et al.  MR Contrast Due to Microscopically Heterogeneous Magnetic Susceptibility: Numerical Simulations and Applications to Cerebral Physiology , 1991, Magnetic resonance in medicine.

[79]  Society of magnetic resonance in medicine , 1990 .

[80]  B. Rosen,et al.  Perfusion imaging with NMR contrast agents , 1990, Magnetic resonance in medicine.

[81]  B. Rosen,et al.  Dynamic imaging with lanthanide chelates in normal brain: Contrast due to magnetic susceptibility effects , 1988, Magnetic resonance in medicine.

[82]  K. Zierler,et al.  On the theory of the indicator-dilution method for measurement of blood flow and volume. , 1954, Journal of applied physiology.